Basic HTML Version
VOLUME 9 NUMBER 2 • JUNE 2012
73
SA JOURNAL OF DIABETES & VASCULAR DISEASE
REPORT
Addition of insulin aspart (NovoRapid) to basal therapy
As fasting plasma glucose levels increase, mealtime insulin secretion
is progressively impaired and clinicians add a quick-acting insulin to
improve control. In this evaluation of the addition of insulin aspart
to basal analogue insulin (Levemir
®
), HbA
1c
level improved, with a
mean reduction of 2.3% over the six months (Fig. 1), as did the FPG
and PPG levels (Fig. 2).
2
Switching from basal insulin glargine to detemir (Levemir
®
)
In a sub-group
2
of almost 1 000 patients who were switched from
insulin glargine to detemir to improve glycaemic control, mean
overall HbA
1c
level was significantly reduced by 1.3% at six months,
while insulin dosage increased from 0.35 to 0.42 U/kg/day (Fig. 3).
Hypoglycaemia was reduced on insulin detemir and quality of life
improved (Fig. 4).
Switching to Novomix (BIAsp 30) from premixed human
insulin
3
This large group (6 326) of patients in the A
1
chieve study, who
started and completed the six-month study on biphasic insulin
aspart, showed a 1.7% reduction in HbA
1c
level over the six
Fig. 4.
Change in HRQoL from baseline to final visit shown as mean EQ-5D questionnaire and VAS score.
Fig. 5.
Change in HbA
1c
after 24 weeks of treatment with BIAsp 30 ± OGLDs in
people previously receiving BHI 30 therapy.
Fig. 3.
Insulin dose change (U/kg) pre-study, baseline and 24 week (final visit).